A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Beijing Cancer Hospital, Beijing

Liaoning Cancer Hospital and Institute, Shenyang

Harbin Medical University Cancer Hospital, Harbin

Fudan University Shanghai Cancer Center, Shanghai

Jiangsu Province Hospital, Nanjing

Affiliated Hospital of Jiangsu University, Zhenjiang

Changzhou Tumor(Fourth Peoples)Hospital, Changzhou

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

The First Peoples Hospital of Lianyungang, Lianyungang

Northern Jiangsu Peoples Hospital, Yangzhou

Shandong Cancer Hospital, Jinan

Weifang Peoples Hospital, Weifang

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Hangzhou Cancer Hospital, Hangzhou

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

Jinhua Municipal Central Hospital, Jinhua

Fujian Cancer Hospital, Fuzhou

The First Affiliated Hospital of Xiamen University, Xiamen

Chongqing Cancer Hospital, Chongqing

Hunan Cancer Hospital, Changsha

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Hubei Cancer Hospital, Wuhan

Henan Cancer Hospital, Zhengzhou

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

The First Affiliated Hospitalschool of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou

Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University ), Jieyang

Sichuan Cancer Hospital and Institute, Chengdu

West China Hospital, Sichuan University, Chengdu

The First Affiliated Hospital of Xian Jiaotong University, Xi'an

Inner Mongolia Autonomous Region Cancer Hospital, Hohhot

Heping Hospital Affiliated to Changzhi Medical College, Changzhi